Dr. Marija Mojić

Dr. Marija Mojić received her Ph.D. in 2013 from the University of Belgrade, Institute for Biological Research “Siniša Stanković” National Institute of the Republic of Serbia. The same year, her doctoral thesis was awarded “Best Doctoral Dissertation”, from the Foundation “Goran Ljubijankić”, Belgrade, Serbia. She spent five years (2014-2019) as a postdoctoral researcher in Prof. Hayakawa’s group in the Division of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama, Japan. There, her research focused on defining the changes in CD8 T cell activation markers in the tumor microenvironment during tumor progression and the changes in the phenotype of immune-escaped tumor cells. Aside from postdoctoral training, Marija also received training at the pharmaceutical company Novartis in Basel, Switzerland (2008) and at the University of Tokyo, Japan (July-September 2009). Since 2020 she has been employed at the Department of Immunology, where her research focuses on exploring anti-cancer properties and mechanism of actions of newly synthetized compounds. Marija is a work package coordinator of the project ADVANCED from the Prisma program, funded by the Science Fund of the Republic of Serbia (2024-2027). She is also an active member of the Serbian Biochemical Society, the European Federation of Biochemical Societies, The Serbian Society for Molecular Biology, the Immunological Society of Serbia, and the European Federation of Immunological Societies.